Press Releases - 2007

	Jerusalem, Israel, December 24, 2007 Teva Announces Launch Of Generic Protonix® Tablets, 20 Mg And 40 Mg, Company Increases 2007 Eps Guidance To Between $2.34 And $2.36, Company To Hold Conference Call At 8:45 A.M. Eastern Time
	Jerusalem, Israel, December 12, 2007 Teva Announces Approval Of Generic Trileptal® Tablets
	Jerusalem, Israel, December 3, 2007 Early Treatment with COPAXONE® Demonstrated Robust Protection against Progression to Clinically Definite Multiple Sclerosis in the PreCISe Study
	Jerusalem, Israel, November 30, 2007 Teva Announces Tentative Approval Of Generic Requip® Tablets
	Jerusalem, Israel and Lund, Sweden, November 7, 2007 Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis
	Jerusalem, Israel, November 6, 2007 First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx® for Leukemia and Lymphoma
	Jerusalem, Israel, October 30, 2007 Teva Announces Planned Retirement Of CFO Dan Suesskind In Mid-2008
	Jerusalem, Israel, October 30, 2007 Teva Reports Third Quarter 2007 Results
	Jerusalem, Israel, October 23, 2007 Copaxone® Significantly Decreases Disease Activity In Patients Who Switched From Interferon Beta (Ifnb) Due To Development Of Neutralizing Antibodies (Nabs)
	Tokyo, Japan/Bristol, TN, USA/Jerusalem, Israel, October 22, 2007 Adenoscan® Patent Lawsuits Settled
	Jerusalem, Israel, October 17, 2007 Teva To Report Third Quarter 2007 Financial Results On OCTOBER 30, 2007
	Jerusalem, Israel, October 15, 2007 Teva Calls 0.375% Remaining Convertible Debentures Due 2022 For Redemption
	Jerusalem, Israel, October 12, 2007 Long-Term Study Shows Copaxone® Significantly Slows Progression Of Disability And Reduces Relapse Rates In Patients With Relapsing-Remitting Multiple Sclerosis
	Jerusalem, Israel, October 8, 2007 Teva Announces Approval Of Generic Actonel®
	Jerusalem, Israel, October 5, 2007 Teva Announces Tentative Approval Of Generic Valtrex®
	Jerusalem, Israel, September 28, 2007 Teva Announces Court Of Appeals Denies Novartis' Emergency Motion On Generic Famvir®
	Jerusalem, Israel, September 27, 2007 Teva Announces Settlement Of Generic Avandia®, Avandamet®, And Avandaryl® Litigation With Glaxosmithkline
	Jerusalem, Israel, September 21, 2007 Teva Provides Update On Generic Neurontin® Litigation
	Jerusalem, Israel, September 19, 2007 Teva Provides Update On Edratide For Systemic Lupus Erythematosus
	Jerusalem, Israel, September 19, 2007 Teva Receives Positive Feedback On Second Aok Tender In Germany
	Jerusalem, Israel, September 16, 2007 Teva Announces Appointment Of Isaac Abravanel As Corporate Vice President, Human Resources
	Jerusalem, Israel, September 8, 2007 Teva Provides Update On Generic Famvir® Litigation
	Jerusalem, Israel, September 7, 2007 Teva Announces Launch Of Generic Famvir® Tablets
	Jerusalem, Israel, September 6, 2007 Teva Receives Favorable Court Decision Regarding Generic Protonix® Tablets; Motion For Preliminary Injunction Denied
	Jerusalem, Israel, September 6, 2007 Teva Announces Approval And Shipment Of Generic Coreg® Tablets
	Jerusalem, Israel, September 5, 2007 Teva Receives Favorable Court Decision Regarding Generic Famvir® Tablets
	Jerusalem, Israel, August 27, 2007 Teva Announces Approval Of Generic Accupril® Tablets
	Jerusalem, Israel, August 24, 2007 Teva Announces Approval Of Generic Famvir® Tablets
	Jerusalem, Israel, August 10, 2007 TEVA ANNOUNCES APPROVAL OF EPIRUBICIN HYDROCHLORIDE INJECTION
	Jerusalem, Israel, August 10, 2007 Teva Announces Tentative Approval Of Sildenafil Citrate Tablets, 20 Mg
	Jerusalem, Israel, August 2, 2007 Teva Announces Approval Of Generic Protonix® Delayed Release Tablets, 20 Mg And 40 Mg
	Jerusalem, Israel, August 1, 2007 Teva Reports Second Quarter 2007 Results
	Jerusalem, Israel, July 17, 2007 Teva To Report Second Quarter 2007 Financial Results On August 1, 2007
	Jerusalem, Israel, July 17, 2007 Teva To Report Second Quarter 2007 Financial Results On August 1, 2007
	Jerusalem, Israel, July 3, 2007 Teva Announces Approval Of Terbinafine Hcl Tablets
	Jerusalem, Israel, July 1, 2007 Teva Announces Approval Of Amlodipine Besylate Tablets
	Jerusalem, Israel, June 28, 2007 Teva Announces Tentative Approval Of Famciclovir Tablets
	Jerusalem, Israel, June 26, 2007 Teva Announces Approval Of Ondansetron Hcl Tablets And Ondansetron Orally Disintegrating Tablets USP
	Jerusalem, Israel, June 12, 2007 Teva Receives Favorable Court Decision Regarding Generic Lotrel®; Novartis' Motion For Preliminary Injunction Denied
	Jerusalem, Israel and Lund, Sweden, June 7, 2007 Teva And Active Biotech To Initiate Pivotal Phase III Trial Program Of Oral Laquinimod For Relapsing Multiple Sclerosis
	Paris, France and Jerusalem, Israel, June 6, 2007 Copaxone® Pre-Filled Syringe Can Now Be Stored For Up To One Month At Room Temperature
	Jerusalem, Israel, May 20, 2007 TEVA PROVIDES UPDATE ON GENERIC LOTREL ®
	Jerusalem, Israel, May 20, 2007 Teva Provides Update On Generic Lotrel ®
	Jerusalem, Israel, May 13, 2007 Teva Comments about the acquisition of generic business of Merck KGaA
	Jerusalem, Israel, May 11, 2007 Teva Provides Update on Generic Aciphex® Litigation
	Jerusalem, Israel, May 10, 2007 Teva Announces Approval and Shipment of Generic Omnicef® Capsules and POS
	Jerusalem, Israel, May 8, 2007 Teva Announces Tentative Approval of Generic Gemzar® for Injection
	Jerusalem, Israel, May 2, 2007, May 2, 2007 Teva Reports First Quarter 2007 Results
	Jerusalem, Israel and Lund, Sweden, May 1, 2007 Laquinimod, A Novel Oral Compound, Showed Significant Reduction In Disease Activity In Patients With Relapsing - Remitting Multiple Sclerosis (RRMS)
	Jerusalem, Israel, April 17, 2007 Data Published In Neurology Showed That Higher Dose Of Copaxone® Increased Efficacy In Relapsing-Remitting Multiple Sclerosis (Rrms)
	Jerusalem, Israel, March 21, 2007 Teva Provides Update On Generic CELEBREX® Litigation
	Jerusalem, Israel, March 11, 2007 Teva Receives First U.S. Approval For Generic UNIRETIC® Tablets
	Jerusalem, Israel, March 8, 2007 Teva Receives Approval For Generic Dostinex® Tablets
	Jerusalem, Israel, March 6, 2007 Teva To Sell Oxycodone Through The End Of 2007
	Jerusalem, Israel, March 5, 2007 Teva Announces Agreement With Biovail And Anchen Regarding Generic Wellbutrin XL®
	Jerusalem, Israel, March 1, 2007 Teva Announces Approval of Alprazolam ER Tablets
	Jerusalem, Israel,, February 13, 2007 Teva Reports Fourth Quarter And Full Year 2006 Results Provides 2007 outlook
	Jerusalem, Israel, February 11, 2007 Shlomo Yanai will assume the role of Teva's President& CEO on March 1st, 2007
	Jerusalem, Israel, February 4, 2007 Teva To Report Fourth Quarter 2006 Financial Results On February 13, 2007
	Jerusalem , Israel, January 30, 2007 Teva Receives Approval for Generic Focalin™ Tablets
	Jerusalem, Israel, January 24, 2007 Teva Files Patent Infringement Complaints Regarding Sertraline Hydrochloride